ROCK CREEK PHARMACEUTICALS INC COM STK (DE)
RCPI
RCPI was delisted on the 4th of November, 2015.
0 hedge funds and large institutions have $0 invested in ROCK CREEK PHARMACEUTICALS INC COM STK (DE) in 2023 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $1 → $0 (-$1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SA
Scarborough Advisors
Annapolis,
Maryland
|
-$1 |
RCPI Hedge Fund Activity: Q3 2023 in Review
0 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in ROCK CREEK PHARMACEUTICALS INC COM STK (DE) (RCPI) for Q3 2023, worth a combined $0 — down 100% from $1 a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of RCPI and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Scarborough Advisors, exiting entirely with an estimated $1 sold.
- 0 institutional investors held ROCK CREEK PHARMACEUTICALS INC COM STK (DE) (RCPI) as of Q3 2023, down from 1 in Q2 2023.
- Funds reported $0 of ROCK CREEK PHARMACEUTICALS INC COM STK (DE) stock for Q3 2023, down 100% quarter-over-quarter.
- 0 funds opened new ROCK CREEK PHARMACEUTICALS INC COM STK (DE) positions in Q3 2023 and 1 closed out, a net change of -1 holder.
- The largest ROCK CREEK PHARMACEUTICALS INC COM STK (DE) seller in Q3 2023 was Scarborough Advisors, an estimated $1 sold.
Based on aggregated 13F filings for Q3 2023.